Qiagen unveils 3 next-generation sequencing panels for cancer R&D

Qiagen HQ
In the third quarter, Qiagen saw 9% growth in its molecular diagnostics offerings, which account for half of the company’s sales. (Qiagen)

Qiagen is launching three next-generation sequencing workflows for cancer research, expanding the clinical oncology footprint of the German company’s GeneReader platform.

Two new GeneRead QIAact panels aim to provide additional genomic insights, with one covering a broad range of cancer-causing variants and the other focusing on genes tied to breast and ovarian cancers. In addition, a new QIAseq panel is being made available for any commercial NGS system to measure the tumor mutational burden biomarker, for assessing patient responses to checkpoint inhibitors.

One feature of the new offerings is the detection of copy number variations down to the exon level, as well as larger, pathogenic deletions, Qiagen said in a statement. The system can also detect alterations in non-coding DNA regions that may undermine tumor-suppressing genes.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The GeneRead QIAact Actionable Insights Tumor DNA UMI panel expands coverage from 12 to 30 genes that influence the progression of cancers of the lung and prostate, as well as melanomas and other solid tumors. It also targets more than 850 DNA variants as well as 125 full exons.

RELATED: FDA approves Qiagen EGFR companion diagnostic to Pfizer’s Vizimpro in first-line NSCLC

Meanwhile, the BRCA Advanced UMI panel analyzes full-exon coding sequences of the BRCA1, BRCA2, TP53 and PTEN genes in breast, ovarian and other cancers.

The TMB panel aims to predict responses to immunotherapies by identifying variants in 486 genes that cover full exons. In a single panel, it can quantify tumor mutational burden, microsatellite instability status, single-nucleotide changes and small insertions or deletions in DNA.

Qiagen also unveiled parallel updates to its bioinformatics solutions, to interpret and report tumor mutation burden and microsatellite instability—as well as a new Qiagen Clinical Insight workflow solution, QCI Analyze Universal, that supports all major clinical sequencing platforms and assay types, the company said.

RELATED: Qiagen launches TB and molecular diagnostic tests with 2 companies

In its third-quarter earnings report, Qiagen saw 9% growth in its molecular diagnostics offerings—which account for half of the company’s sales—supported by its latent tuberculosis test and companion diagnostic co-development projects with pharma companies.

Total net sales grew 3.8% to $377.9 million compared to the third quarter of 2017, following a 2.7 percentage-point reduction due to adverse currency movements against the U.S. dollar, the company said. Qiagen posted a net income of $60.3 million; a 24.3% increase compared to the $48.5 million brought in during the same quarter last year.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.